Columbia neuroscientists have identified a genetic mutation that fends off Alzheimer's in people at high risk and could lead to a new way to protect people from the disease.
ADScreen, a speech-processing algorithm developed at Columbia Nursing, is now being tested in a clinical trial to see if it can help health care workers identify patients with Alzheimer's earlier.
Lecanemab, marketed as Leqembi, is the first drug for Alzheimer’s disease to receive approval on the basis of clinically slowing the progression of Alzheimer’s disease.
Attending a high school with a high number of teachers with graduate training was the clearest predictor of the impact of school quality on late-life cognition, researchers found.
CUMC's Dr. Eric Kandel (2000 Nobel Laureate) said the project may lead to an understanding of "who we are as human beings and how we function and how these terrible diseases arise, and what we might be able to do address them more effectively."
The virus that causes cold sores, along with other viral or bacterial infections, may be associated with cognitive problems; a new study from CUMC's Mira Katan and Mitch Elkind.
More symptoms of depression and lower cognitive status are independently associated with a more rapid decline in the ability to handle tasks of everyday living, according to a study by CUMC researchers.
Depression appears to be associated with mild cognitive impairment and an increased risk of dementia; José A. Luchsinger, MD, MPH was senior author of the study, published in the Archives of Neurology.